Fulminant Secondary HLH Following EBV Reactivation in an Adult With Trisomy 21 After Teplizumab Treatment for Stage 2 Type 1 Diabetes

Diabetes Care · Available online 28 Jul 2026 · In press · DOI 10.2337/dc26-0543

Free full text

Authors (2)

Christian Klemann, Olga Kordonouri

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Klemann, C., Kordonouri, O. (2026). Fulminant Secondary HLH Following EBV Reactivation in an Adult With Trisomy 21 After Teplizumab Treatment for Stage 2 Type 1 Diabetes. Diabetes Care. https://doi.org/10.2337/dc26-0543

Related articles

• Issues and Events · Diabetes Care · 2026 · Same journal
• Reactive Hypoglycemia as a Transient Metabolic Phenotype of Stage 1 and 2 Type 1 Diabetes · Diabetes Care · 2026 · Same journal
• IgG N-Glycosylation and Incident Neuropathy and Nephropathy in People With Type 2 Diabetes: A Pooled Analysis of Prospective Cohort Studies · Diabetes Care · 2026 · Same journal
• National Trends in Out-of-Pocket Cost for Glucose-Lowering Drugs Among U.S. Adults With Diabetes, 2000–2022 · Diabetes Care · 2026 · Same journal
• Data-Driven Subclassification of Prediabetes and Diabetes in South Asian Adults From India · Diabetes Care · 2026 · Same journal
• Melatonin Impairs Glucose Tolerance, First-Phase Insulin Secretion, and Insulin Feedback Inhibition; Interaction With MTNR1B Diabetes Risk Variant · Diabetes Care · 2026 · Same journal
• Clinical and Biochemical Recovery From Immune Checkpoint Inhibitor–Induced Diabetes With Seroconversion of GAD Antibodies · Diabetes Care · 2026 · Same journal
• Sarcopenic Obesity and Risk of Incident Type 2 Diabetes: A Prospective Cohort Study and Landmark Analysis From the UK Biobank · Diabetes Care · 2026 · Same journal
• What Makes the Difference? Predicting Glycemic Trajectories Following Initiation of Automated Insulin Delivery Systems in Youth With Type 1 Diabetes · Diabetes Care · 2026 · Same journal
• Study of Metformin and GLP-1 Receptor Agonist Use in Hidradenitis Suppurativa Using the NIH All of Us Research Program · Diabetes Care · 2026 · Same journal